OBJECTIVE: Copy number variation is a common polymorphic phenomenon within the human genome. Although the majority of these events are non-deleterious they can also be highly pathogenic. Herein we characterize five families with parkinsonism that have been identified to harbor multiplication of the chromosomal 4q21 locus containing the alpha-synuclein gene (SNCA). METHODS: A methodological approach using fluorescent in situ hybridization and Affymetrix (Santa Clara, CA) 250K SNP microarrays was used to characterize the multiplication in each family and to identify the genes encoded within the region. The telomeric and centromeric breakpoints of each family were further narrowed using semiquantitative polymerase chain reaction with microsatellite markers and then screened for transposable repeat elements. RESULTS: The severity of clinical presentation is correlated with SNCA dosage and does not appear to be overtly affected by the presence of other genes in the multiplicated region. With the exception of the Lister kindred, in each family the multiplication event appears de novo. The type and position of Alu/LINE repeats are also different at each breakpoint. Microsatellite analysis demonstrates two genomic mechanisms are responsible for chromosome 4q21 multiplications, including both SNCA duplication and recombination. INTERPRETATION: SNCA dosage is responsible for parkinsonism, autonomic dysfunction, and dementia observed within each family. We hypothesize dysregulated expression of wild-type alpha-synuclein results in parkinsonism and may explain the recent association of common SNCA variants in sporadic Parkinson's disease. SNCA genomic duplication results from intraallelic (segmental duplication) or interallelic recombination with unequal crossing over, whereas both mechanisms appear to be required for genomic SNCA triplication.
OBJECTIVE: Copy number variation is a common polymorphic phenomenon within the human genome. Although the majority of these events are non-deleterious they can also be highly pathogenic. Herein we characterize five families with parkinsonism that have been identified to harbor multiplication of the chromosomal 4q21 locus containing the alpha-synuclein gene (SNCA). METHODS: A methodological approach using fluorescent in situ hybridization and Affymetrix (Santa Clara, CA) 250K SNP microarrays was used to characterize the multiplication in each family and to identify the genes encoded within the region. The telomeric and centromeric breakpoints of each family were further narrowed using semiquantitative polymerase chain reaction with microsatellite markers and then screened for transposable repeat elements. RESULTS: The severity of clinical presentation is correlated with SNCA dosage and does not appear to be overtly affected by the presence of other genes in the multiplicated region. With the exception of the Lister kindred, in each family the multiplication event appears de novo. The type and position of Alu/LINE repeats are also different at each breakpoint. Microsatellite analysis demonstrates two genomic mechanisms are responsible for chromosome 4q21 multiplications, including both SNCA duplication and recombination. INTERPRETATION:SNCA dosage is responsible for parkinsonism, autonomic dysfunction, and dementia observed within each family. We hypothesize dysregulated expression of wild-type alpha-synuclein results in parkinsonism and may explain the recent association of common SNCA variants in sporadic Parkinson's disease. SNCA genomic duplication results from intraallelic (segmental duplication) or interallelic recombination with unequal crossing over, whereas both mechanisms appear to be required for genomic SNCA triplication.
Authors: A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy Journal: Science Date: 2003-10-31 Impact factor: 47.728
Authors: M Farrer; D M Maraganore; P Lockhart; A Singleton; T G Lesnick; M de Andrade; A West; R de Silva; J Hardy; D Hernandez Journal: Hum Mol Genet Date: 2001-08-15 Impact factor: 6.150
Authors: Javier Simon-Sanchez; Sonja Scholz; Maria del Mar Matarin; Hon-Chung Fung; Dena Hernandez; J Raphael Gibbs; Angela Britton; John Hardy; Andrew Singleton Journal: Hum Mutat Date: 2008-02 Impact factor: 4.878
Authors: Marshall E Lieberfarb; Ming Lin; Mirna Lechpammer; Cheng Li; David M Tanenbaum; Phillip G Febbo; Renée L Wright; Judy Shim; Philip W Kantoff; Massimo Loda; Matthew Meyerson; William R Sellers Journal: Cancer Res Date: 2003-08-15 Impact factor: 12.701
Authors: Matt Farrer; Jennifer Kachergus; Lysia Forno; Sarah Lincoln; Deng-Shun Wang; Mary Hulihan; Demetrius Maraganore; Katrina Gwinn-Hardy; Zbigniew Wszolek; Dennis Dickson; J William Langston Journal: Ann Neurol Date: 2004-02 Impact factor: 10.422
Authors: Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday Journal: Nat Med Date: 2010-05-23 Impact factor: 53.440
Authors: Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami Journal: J Neurol Neurosurg Psychiatry Date: 2010-09-30 Impact factor: 10.154
Authors: Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton Journal: Mol Neuropsychiatry Date: 2015-07-08
Authors: Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek Journal: Hum Mol Genet Date: 2014-04-28 Impact factor: 6.150
Authors: C Perandones; J C Giugni; D S Calvo; G B Raina; L De Jorge Lopez; V Volpini; C P Zabetian; I F Mata; M Caputo; D Corach; M Radrizzani; F E Micheli Journal: Parkinsonism Relat Disord Date: 2013-11-27 Impact factor: 4.891